Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00059943
Status:
COMPLETED
Last Update Posted:
2013-01-16
First Post:
2003-05-06
Brief Title:
Docetaxel in Treating Older Patients With Metastatic Breast Lung or Prostate Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Pharmacokinetics of Weekly Docetaxel in Patients Age 65 and Older With Metastatic Breast or Lung Cancer
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy such as docetaxel use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE This phase II trial is studying how well docetaxel works in treating older patients with metastatic breast lung or prostate cancer
PURPOSE This phase II trial is studying how well docetaxel works in treating older patients with metastatic breast lung or prostate cancer
Detailed Description:
OBJECTIVES
Determine the pharmacokinetics of docetaxel in older patients with metastatic breast lung or prostate cancer
Determine the response of patients treated with this drug
Determine the toxicity of this drug in these patients
Determine the short-term changes in functional status in terms of activities of daily living independent activities of daily living and Karnofsky performance status in patients treated with this drug
Correlate the number of comorbid conditions at baseline with declines in functional status in patients treated with this drug
OUTLINE Patients receive docetaxel IV over 30 minutes once weekly for 3 weeks Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 20 patients will be accrued for this study within 1 year
Determine the pharmacokinetics of docetaxel in older patients with metastatic breast lung or prostate cancer
Determine the response of patients treated with this drug
Determine the toxicity of this drug in these patients
Determine the short-term changes in functional status in terms of activities of daily living independent activities of daily living and Karnofsky performance status in patients treated with this drug
Correlate the number of comorbid conditions at baseline with declines in functional status in patients treated with this drug
OUTLINE Patients receive docetaxel IV over 30 minutes once weekly for 3 weeks Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 20 patients will be accrued for this study within 1 year
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MSKCC-01136 | None | None | None |